Accordingly, the invention particularly extends to a method for modulating the in vivo aggregation of ??AP and associated neurodegenerative amyloidosis by controlling the formation and presence of AGE-??AP. The invention further particularly extends to a method for modulating the in vivo aggregation of amylin and associated pancreatic islet cell amyloidosis by controlling formation and presence of